Association of CYP2C19*17/*17 Genotype With the Risk of Voriconazole- Associated Squamous Cell Carcinoma

被引：12
|
作者：
Williams, Kiyanna [1 ]
Arron, Sarah T. [2 ]
机构：
[1] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Dermatol, 1701 Divisadero St,3rd Floor, San Francisco, CA 94115 USA
来源：
JAMA DERMATOLOGY | 2016年 / 152卷 / 06期
关键词：
TRANSPLANT RECIPIENTS; ANTIFUNGAL AGENT; CYP2C19;
D O I：
10.1001/jamadermatol.2016.0351
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：719 / 720
页数：2
相关论文
共 50 条
  • [1] High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype
    Bennis, Youssef
    Bodeau, Sandra
    Bouquie, Regis
    Deslandes, Guillaume
    Verstuyft, Celine
    Gruson, Berangere
    Andrejak, Michel
    Lemaire-Hurtel, Anne-Sophie
    Chouaki, Taieb
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (04) : 782 - 784
  • [2] Clinical importance of the CYP2C19*17 variant allele for voriconazole
    Dolton, Michael J.
    McLachlan, Andrew J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (01) : 137 - 138
  • [3] CYP2C19*17 is associated with decreased breast cancer risk
    Christina Justenhoven
    Ute Hamann
    Christiane B. Pierl
    Christian Baisch
    Volker Harth
    Sylvia Rabstein
    Anne Spickenheuer
    Beate Pesch
    Thomas Brüning
    Stefan Winter
    Yon-Dschun Ko
    Hiltrud Brauch
    Breast Cancer Research and Treatment, 2009, 115 : 391 - 396
  • [4] CYP2C19*17 is associated with decreased breast cancer risk
    Justenhoven, Christina
    Hamann, Ute
    Pierl, Christiane B.
    Baisch, Christian
    Harth, Volker
    Rabstein, Sylvia
    Spickenheuer, Anne
    Pesch, Beate
    Bruening, Thomas
    Winter, Stefan
    Ko, Yon-Dschun
    Brauch, Hiltrud
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) : 391 - 396
  • [5] Voriconazole-induced hyponatraemia associated with homozygous CYP2C19*2 genotype
    Ho, Sharon
    Rawlins, Matthew
    Ingram, Paul
    Boan, Peter
    JOURNAL OF CHEMOTHERAPY, 2017, 29 (05) : 325 - 326
  • [6] Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
    Klomp, Sylvia D.
    Veringa, Anette
    Alffenaar, Jan-Willem C.
    de Boer, Mark G. J.
    Span, Lambert F. R.
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (07):
  • [7] A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine
    Malingre, Mirte M.
    Godschalk, Peggy C. R.
    Klein, Saskia K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (01) : 205 - 206
  • [8] Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole
    Mangal, Naveen
    Hamadeh, Issam
    Samant, Tanay
    Schmidt, Stephan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S53 - S53
  • [9] The CYP2C19*17 variant is not independently associated with clopidogrel response
    Lewis, J. P.
    Stephens, S. H.
    Horenstein, R. B.
    O'Connell, J. R.
    Ryan, K.
    Peer, C. J.
    Figg, W. D.
    Spencer, S. D.
    Pacanowski, M. A.
    Mitchell, B. D.
    Shuldiner, A. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1640 - 1646
  • [10] CYP2C19*17 genetic polymorphism-an uncommon cause of voriconazole treatment failure
    Abidi, Maheen Z.
    D'Souza, Anita
    Kuppalli, Krutika
    Ledeboer, Nathan
    Hari, Parmeswaran
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 83 (01) : 46 - 48
12345